High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$4.7M
$4,671,277
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
MAZE
S
Maze Therapeutics, Inc.
Bachrodt Amy
• Officer • SVP, Finance
10b5-1 Sell
2026-03-02
$226,011x2
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
10b5-1 Sell
|
2026-03-02 | $226,011x2 | S | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Dandekar Atul
• Officer • CSBO
10b5-1 SellΔOwn -20.8%
2026-02-27
$340,723x2
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • CSBO
10b5-1 SellΔOwn -20.8%
|
2026-02-27 | $340,723x2 | S | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Bachrodt Amy
• Officer • SVP, Finance
10b5-1 Sell
2026-02-02
$230,219x3
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
10b5-1 Sell
|
2026-02-02 | $230,219x3 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
President
10b5-1 Sell
|
2026-02-02 | $690,334x4 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Officer • CSBO
10b5-1 Sell
|
2026-01-29 | $331,990x3 | S | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Bachrodt Amy
• Officer • SVP, Finance
10b5-1 SellΔOwn -27.8%
2026-01-22
$227,612
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Officer • SVP, Finance
10b5-1 SellΔOwn -27.8%
|
2026-01-22 | $227,612 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
President
10b5-1 Sell
|
2026-01-07 | $1,011,299Large | S | Form 4 |
|
MAZE
S
Maze Therapeutics, Inc.
Sohn Catherine A.
• Director
Discretionary Sell
2026-01-07
$1,052,785Large
|
||||||
| MAZE |
Maze Therapeutics, Inc.
|
Director
Discretionary Sell
|
2026-01-07 | $1,052,785Large | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Discretionary Sell
|
2026-01-06 | $96,270 | S | Form 4 |
| MAZE |
Maze Therapeutics, Inc.
|
Director
Discretionary Sell
|
2025-09-15 | $464,035 | S | Form 4 |